A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

A proprietary monoclonal antibody targeting an inhibitory immune checkpoint pathway had favorable safety and tolerability in ...

Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

Immune checkpoint inhibitors have reshaped cancer treatment over the past decade, but the same immune activation that shrinks tumors can also turn against healthy tissue, including the brain. A ...

Immunotherapy has been one of the most transformative treatments for cancer patients in recent decades, shifting the emphasis ...

Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability-High Gastric Cancer: Solid Evidence or Premature Extrapolation? The following represents disclosure information ...

A metabolic enzyme found in the support cells surrounding tumors may hold the key to predicting which cancer patients will ...